Creative Medical Technology (CELZ) Stock Price, News & Analysis

Company Overview

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction. Creative Medical collaborates with research institutions and clinical sites to advance its pipeline through preclinical and clinical studies, seeking to validate safety and efficacy across multiple therapeutic areas. The firm also develops ancillary products for in‐office administration by healthcare professionals, emphasizing ease of use and regulatory compliance.

Headquartered in Scottsdale, Arizona, Creative Medical serves a network of medical clinics, plastic surgery centers and sports medicine practices across the United States, with growing distribution in select international markets. The company’s team combines expertise in stem cell biology, exosome science and regulatory affairs to support product advancement and market access. Creative Medical continues to explore strategic partnerships to expand its research capabilities and commercial footprint.

Since its inception, Creative Medical has pursued a mission to harness the regenerative potential of exosomes without the complexities of live cell therapies. Through ongoing research, process optimization and quality control, the company aims to deliver innovative treatment options that address unmet clinical needs in tissue repair and aesthetic enhancement. Management comprises experienced professionals in biotechnology development, quality assurance and regulatory strategy, guiding the company toward clinical milestones and commercial readiness.

Key Stats

• Today's Range: $2.32 to $2.40
• 50-Day Range: $1.81 to $2.47
• 52-Week Range: $1.50 to $6.25
• Volume: 47,690 shs
• Average Volume: 55,877 shs
• Market Capitalization: $8.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Creative Medical Technology Stock Analysis - MarketRank™

Creative Medical Technology scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Creative Medical Technology has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Creative Medical Technology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Creative Medical Technology are expected to grow in the coming year, from ($1.57) to ($1.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Creative Medical Technology is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Creative Medical Technology is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Creative Medical Technology has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.90% of the float of Creative Medical Technology has been sold short.

Short Interest Ratio / Days to Cover

Creative Medical Technology has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Creative Medical Technology has recently decreased by 9.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Creative Medical Technology does not currently pay a dividend.

Dividend Growth

Creative Medical Technology does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Creative Medical Technology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Creative Medical Technology insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Creative Medical Technology is held by insiders.

Percentage Held by Institutions

1.42% of the stock of Creative Medical Technology is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/26/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELZ
• CIK: 1187953
• Web: www.creativemedicaltechnology.com
• Phone: (833) 336-7636
• Fax: N/A
• Employees: 5
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($2.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.99 million
• Net Margins: N/A
• Pretax Margin: -192,033.34%
• Return on Equity: -88.38%
• Return on Assets: -84.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.67
• Quick Ratio: 19.67

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 884.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 3,700,000
• Free Float: 3,634,000
• Market Cap: $8.84 million
• Optionable: Not Optionable
• Beta: 1.87